• Dr. Olivia Van Gerwen completed her internal medicine residency and chief residency at Tulane University in New Orleans, LA. She returned to her hometown of Birmingham, AL to pursue a fellowship in Infectious Diseases at UAB, which she completed in 2020 in addition to a post-doctoral fellowship in health services, outcomes, and effectiveness research. She is now an Assistant Professor in the UAB Division of Infectious Diseases. Olivia's research focuses on HIV and STI prevention as well as comprehensive sexual health promotion among transgender populations. Clinically, she enjoys providing sexual healthcare services to patients at the UAB Gender Health clinic as well as patients living with HIV at the UAB 1917 Clinic.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Bacterial Vaginosis in Postmenopausal WomenCurrent Infectious Disease Reports.  25:7-15. 2023
    2022 Sexually transmitted infections and female reproductive healthNature Microbiology.  7:1116-1126. 2022
    2022 Human Immunodeficiency Virus/Sexually Transmitted Infection Testing Preferences for Young Black Men Who Have Sex with Men in the Southeastern United States: Implications for a Post-COVID-19 EraSexually Transmitted Diseases.  49:208-215. 2022
    2022 Anatomical and sexual health considerations among transfeminine individuals who have undergone vaginoplasty: A reviewInternational Journal of STD and AIDS.  33:106-113. 2022
    2022 "It's behaviors, not identity": Attitudes and beliefs related to HIV risk and pre-exposure prophylaxis among transgender women in the Southeastern United StatesPLoS One.  17. 2022
    2022 The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern U.S.AIDS and Behavior2022
    2021 Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysisBJOG: an International Journal of Obstetrics and Gynaecology.  128:1907-1915. 2021
    2021 Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment StudyClinical Infectious Diseases.  73:E1282-E1289. 2021
    2021 Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in MenClinical Infectious Diseases.  73:1119-1124. 2021
    2021 Management of Trichomoniasis in the Setting of 5-Nitroimidazole HypersensitivitySexually Transmitted Diseases.  48:E111-E115. 2021
    2021 Prevalence of and Factors Associated with Genital and Extragenital Chlamydia and Gonorrhea among Transgender Women in HIV Care in the United States, 2005 to 2016Sexually Transmitted Diseases.  48:410-416. 2021
    2020 Prevalence of Sexually Transmitted Infections and Human Immunodeficiency Virus in Transgender Persons: A Systematic ReviewTransgender Health.  5:90-103. 2020
    2020 Updates in trichomonas treatment including persistent infection and 5-nitroimidazole hypersensitivityCurrent Opinion in Infectious Diseases.  33:73-77. 2020
    2019 Recent advances in the epidemiology, diagnosis, and management of trichomonas vaginalis infection [version 1; peer review: 2 approved]F1000Research.  8. 2019

    Education And Training

  • Tulane University School of Medicine Internal Medicine, Chief Resident
  • University of Alabama at Birmingham Health Services, Outcomes, and Effectiveness Research, Postdoctoral Research
  • Tulane University School of Medicine Internal Medicine, Residency
  • University of Alabama at Birmingham Infectious Diseases, Postdoctoral Fellowship
  • Doctor of Medicine, University of Alabama at Birmingham 2014
  • Master of Public Health, University of Alabama at Birmingham 2010
  • Bachelor of Arts in Spanish Language and Literature, University of Alabama at Birmingham 2009
  • Bachelor of Science or Mathematics in Biology, University of Alabama at Birmingham 2009
  • Full Name

  • Olivia Van Gerwen